Pipeline

Genetics reveals an entirely new approach to resolving inflammation

Nucleome’s technology generates a highly productive, repeatable process for the discovery of novel therapeutic targets. In addition to developing our own pipeline of inflammatory disease medicines, we are selectively partnering with pharmaceutical companies and expanding our approach to address additional applications and therapeutic areas.

NTP464

A first-in-class antibody targeting a key regulator of inflammation resolution, with cellular pharmacological effects on both adaptive and innate immunity:

Target of NTP464 was revealed by a genetic variant affecting multiple immune cell types in multiple inflammatory diseases.
Antibody stimulation of the protein on activated immune cells induces regulatory responses.
NTP464 is in pre-clinical development with clinical trial application and commencement of a Phase 1 clinical trial targeted for 2027
NTP464 mechanism of action suggests the potential for broad clinical application, with initial clinical indication in Rheumatoid Arthritis and SLE.

Pipeline

Multiple additional targets are undergoing biological validation and early stage discovery, supported by MCC and AI/ML-driven variant-to-gene mapping. We have identified targets we are pursuing for internal development and for partnership.

Inflammatory Disease

Immune-mediated inflammatory diseases are chronic inflammatory diseases caused by immune system dysregulation, encompassing a wide range of conditions including autoimmune diseases and rheumatic diseases that affect multiple organs and systems, including asthma, atopic dermatitis, psoriasis, type 1 diabetes, multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, and systemic lupus erythematosus.¹

The global market for autoimmune and chronic inflammatory disease therapeutics reflects this opportunity. Projected to grow significantly, reaching between $226bn and $250bn by the mid-2030s, this rise is driven not only by increasing disease prevalence but also by advances in our understanding of immune system biology.²

There are currently no known cures for the ~3-7% of people in the Western world affected by immune-mediate inflammatory diseases^3,4. Current treatments help to reduce inflammation, relieve pain and slow down some disease progression by effective management of the disease. However, side-effects of current anti-inflammatory drugs can preclude treatment including stomach ulcers, indigestion, weight gain, mood change, increased blood pressure and gastrointestinal bleeding, as well as more severe events such as heart attacks and stroke⁵. The anti-inflammatory drugs market is currently divided into treatments using biologics, nonsteroidal anti-inflammatory drugs (NSAIDS), corticosteroids and other drug classes.

Science

1. https://www.worldallergyorganizationjournal.org/article/S1939-4551(25)00008-0/fulltext
2. https://insights.citeline.com/in-vivo/innovation/restoring-immune-balance
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC9312038/
4. https://www.nature.com/articles/s41577-021-00603-1#:~:text=Immune%2Dmediated%20inflammatory%20diseases%20(IMIDs,there%20are%20no%20current%20cures.
5. https://www.gminsights.com/industry-analysis/anti-inflammatory-drugs-market#:~:text=Anti%2Dinflammatory%20Drugs%20Industry%20Analysis,coupled%20with%20growing%20geriatric%20population

Partnering

Nucleome is collaborating with a major pharmaceutical company and foresees multiple opportunities to collaborate with other companies to identify targets and responsive patients in a variety of therapeutic areas.